Roche has posted a mixed set of data from two clinical trials of its anti-IL-33/ST2 antibody astegolimab in chronic obstructive pulmonary disease (COPD), casting a shadow over the programme. On the ...
Expertise from Forbes Councils members, operated under license. Opinions expressed are those of the author. Membership (fee-based) Forbes Technology Council is an invitation-only, fee-based ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback